Patient/parent perspectives on genomic tumor profiling of pediatric solid tumors: The Individualized Cancer Therapy (iCat) experience.

scientific article published on 18 July 2016

Patient/parent perspectives on genomic tumor profiling of pediatric solid tumors: The Individualized Cancer Therapy (iCat) experience. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1002/PBC.26137
P932PMC publication ID5611837
P698PubMed publication ID27429135

P50authorJonathan M MarronQ59159134
P2093author name stringKatherine A Janeway
Steven G DuBois
Jennifer W Mack
AeRang Kim
Brian D Crompton
Julia Glade Bender
Stephanie C Meyer
P2860cites workFuture of clinical genomics in pediatric oncology.Q38099310
Translating genomic discoveries to the clinic in pediatric oncologyQ38287241
Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors: The Individualized Cancer Therapy (iCat) Study.Q38382479
Overcoming challenges to meaningful informed consent for whole genome sequencing in pediatric cancer research.Q39022681
Pooled analysis of phase II window studies in children with contemporary high-risk metastatic rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology GroupQ40306049
Post-relapse survival in patients with Ewing sarcomaQ41587144
Diagnostic Yield of Clinical Tumor and Germline Whole-Exome Sequencing for Children With Solid TumorsQ41783629
Improving Patient Outcomes With Cancer Genomics: Unique Opportunities and Challenges in Pediatric OncologyQ43227846
Genomic testing in cancer: patient knowledge, attitudes, and expectationsQ47755758
Understanding of prognosis among parents of children with cancer: parental optimism and the parent-physician interactionQ50904864
Evaluating the quality of informed consentQ57194143
Basket Trials and the Evolution of Clinical Trial Design in an Era of Genomic MedicineQ63199223
Understanding of prognosis among parents of children who died of cancer: impact on treatment goals and integration of palliative careQ73180387
NCI-MATCH launch highlights new trial design in precision-medicine eraQ85528297
The Genetic Knowledge Index: developing a standard measure of genetic knowledgeQ93925647
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastomaQ24602657
Improved survival with vemurafenib in melanoma with BRAF V600E mutationQ24631953
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.Q27824766
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancerQ27851588
Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.Q27852211
First-line crizotinib versus chemotherapy in ALK-positive lung cancerQ27853101
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 MutationsQ27853199
ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencingQ29616235
Obtaining informed consent for clinical tumor and germline exome sequencing of newly diagnosed childhood cancer patientsQ30591763
Is Whole-Exome Sequencing an Ethically Disruptive Technology? Perspectives of Pediatric Oncologists and Parents of Pediatric Patients With Solid TumorsQ30798291
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosomeQ33336718
Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).Q33398716
Parents' preferences for return of results in pediatric genomic researchQ33815053
Quality of informed consent: a new measure of understanding among research subjectsQ33935042
Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.Q33964848
Declining childhood and adolescent cancer mortalityQ34060045
Clinical tumor sequencing: an incidental casualty of the American College of Medical Genetics and Genomics recommendations for reporting of incidental findings.Q34299861
Survival of pediatric patients after relapsed osteosarcoma: the St. Jude Children's Research Hospital experience.Q34754346
Motivations and Perceptions of Early Adopters of Personalized Genomics: Perspectives from Research ParticipantsQ35576348
Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups.Q36022696
Improving the outcome for children with cancer: Development of targeted new agentsQ36238795
Effects of informed consent for individual genome sequencing on relevant knowledgeQ36312837
Attitudes of patients with cancer about personalized medicine and somatic genetic testingQ36406057
Germline Mutations in Predisposition Genes in Pediatric CancerQ36524309
Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in YouthQ36592140
Testing personalized medicine: patient and physician expectations of next-generation genomic sequencing in late-stage cancer careQ37585888
Public understandings of genetics and healthQ37679305
Physicians' attitudes about multiplex tumor genomic testingQ37712065
Systematic Review of Psychosocial Benefits and Harms of Genetic TestingQ37790364
Recall bias in epidemiologic studiesQ38063468
P433issue11
P304page(s)1974-1982
P577publication date2016-07-18
P1433published inPediatric Blood & CancerQ15754342
P1476titlePatient/parent perspectives on genomic tumor profiling of pediatric solid tumors: The Individualized Cancer Therapy (iCat) experience
P478volume63

Reverse relations

cites work (P2860)
Q89908298Cancer Patient-Reported Preferences and Knowledge for Liquid Biopsies and Blood Biomarkers at a Comprehensive Cancer Center
Q93031372Duality of purpose: Participant and parent understanding of the purpose of genomic tumor profiling research among children and young adults with solid tumors
Q39363424Ethical considerations in genomic testing for hematologic disorders
Q63446437Exome sequencing disclosures in pediatric cancer care: Patterns of communication among oncologists, genetic counselors, and parents
Q91842359Molecular characteristics and therapeutic vulnerabilities across paediatric solid tumours
Q61452080Next-generation sequencing in precision oncology: Patient understanding and expectations
Q92739755Patients' views on variants of uncertain significance across indications
Q47392557Precision medicine in pediatric oncology
Q90731740Precision oncology: lessons learned and challenges for the future

Search more.